Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 206,300 shares, an increase of 16.7% from the August 15th total of 176,800 shares. Based on an average daily volume of 180,900 shares, the days-to-cover ratio is currently 1.1 days.
Microbot Medical Price Performance
MBOT traded down $0.02 during trading hours on Tuesday, reaching $0.94. 239,035 shares of the stock traded hands, compared to its average volume of 1,025,557. Microbot Medical has a fifty-two week low of $0.82 and a fifty-two week high of $2.35. The company has a market cap of $14.96 million, a price-to-earnings ratio of -1.05 and a beta of 1.64. The firm’s fifty day simple moving average is $0.98 and its two-hundred day simple moving average is $1.04.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). On average, research analysts predict that Microbot Medical will post -0.66 earnings per share for the current year.
Analyst Ratings Changes
View Our Latest Analysis on Microbot Medical
Institutional Investors Weigh In On Microbot Medical
An institutional investor recently bought a new position in Microbot Medical stock. Thoroughbred Financial Services LLC acquired a new stake in shares of Microbot Medical Inc. (NASDAQ:MBOT – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 52,250 shares of the biotechnology company’s stock, valued at approximately $53,000. Thoroughbred Financial Services LLC owned approximately 0.33% of Microbot Medical as of its most recent SEC filing. Institutional investors and hedge funds own 16.30% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
- Five stocks we like better than Microbot Medical
- How to Invest in the Best Canadian StocksÂ
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Using the MarketBeat Dividend Yield Calculator
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.